Patents by Inventor David S. Block

David S. Block has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoglobulin constant region FC receptor binding agents
    Patent number: 8680237
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 25, 2014
    Assignees: Gliknik Inc., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
    Publication number: 20130156765
    Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.
    Type: Application
    Filed: July 28, 2011
    Publication date: June 20, 2013
    Inventors: David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20120309941
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 6, 2012
    Applicants: GLIKNIK, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20100239633
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 30, 2008
    Publication date: September 23, 2010
    Applicant: UNIVERSITY OF MARYLAND BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block